is the recipient of the Walter Benjamin Fellowship from the German Research Association (DFG) project number 462524713 and the EASO-Novo Nordisk Foundation New Investigator Award: Clinical Research, project number NNF25SA010378
Metabolic syndrome and associated chronic kidney diseases: Nutritional interventions
showed that GGT7 could directly bind to RAB7 to induce autophagy, inhibited ROS and MAPK cascade responses, and played a key tumour-suppressive role in gastric cancer [24]
Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD
A vlasztsnl figyelni kell a hatanyag formjra, mennyisgre s a kiegszt sszetevkre
